ArticleCancers2023
Circadian Disruption and Breast Cancer Risk: Evidence from a Case-Control Study in China.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- The Relationship Between Climate Change and Breast Cancer and Its Management and Preventative Implications in South Africa.International journal of environmental research and public health · 2025Pooled it
- Light at night exposure and risk of breast cancer: a meta-analysis of observational studies.Frontiers in public health · 2023Pooled it
- Association between circadian rhythm-related behaviors and breast cancer: a bidirectional Mendelian randomization study.Future science OA · 2026Article
- Risk Factors and Prediction of Chronic Obstructive Pulmonary Disease After Pulmonary Tuberculosis: A Prospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Neuro-immune crosstalk in breast cancer: molecular mechanisms from stress signals to immune escape.Frontiers in immunology · 2026Review
- Insomnia in Women Surviving Breast and Gynecological Cancers-A Narrative Review to Address the Hormonal Factor.Cancers · 2025Review
- Night shift work and breast cancer risk - 2023 update of epidemiologic evidence.Journal of the National Cancer Center · 2025Review
- HGH1 Promotes Breast Cancer Progression Through the PI3K/AKT/NF-κB Signaling Pathway: Potential Role for Prognosis and Targeted Therapy.Breast cancer (Dove Medical Press) · 2025Article
- Exposure to Light at Night and Risk of Cancer: A Systematic Review, Meta-Analysis, and Data Synthesis.Cancers · 2024Review
- Article
- Biological clock regulation by theFrontiers in cell and developmental biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Studies had suggested an association between circadian disruptors (including night shift work, domestic light exposure at night, sleep duration, and circadian gene polymorphism) and breast cancer, while rare studies had been conducted in the Chinese population. This study was a case-control study conducted to explore the impact of circadian disruptors on the risk of breast cancer in China. Four hundred and sixty-four cases and 464 controls, admitted from the Department of Breast Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, were included in this study. Adjusting age, BMI group, smoking, alcohol consumption, menopausal status, family history of breast cancer, duration of breastfeeding, age at menarche, number of pregnancies, age at first full-term pregnancy, use of estrogen and use of oral contraceptive, multivariate logistic regression analysis showed that the risk of breast cancer was higher in short sleep duration group (OR = 4.86, 95%CI: 1.73-17.33). Meanwhile, rs2292912 in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.